1921
Volume 96, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

The United States has a low burden of drug resistance among tuberculosis (TB) cases compared with other world regions. TB is increasingly concentrated among foreign-born individuals who have higher rates of drug resistance than U.S.-born individuals. While universal drug susceptibility testing is the standard for detecting active tuberculosis, there are limited guidelines for latent tuberculosis infection (LTBI) treatment based on risk factors for drug resistance. To quantify the variable risk of drug resistance among foreign-born individuals, all TB cases in Washington State between 1994 and 2014 with drug resistance data for isoniazid, rifampin, pyrazinamide, and ethambutol were divided into eight regions of birth. Logistic regression was used to characterize regional differences in resistance patterns. Genotypic cluster and lineage data were compared against drug resistance in a subanalysis. Among 4,298 cases, isoniazid resistance was more common in foreign-born individuals (12.6% versus 4.8%; < 0.001), with the highest burden among individuals from the Asia-Pacific (14.8%) region. Rifampin resistance was slightly higher among foreign-born individuals (1.9% versus 1.1%; = 0.063). Multivariate logistic regression demonstrated that older age was associated with a lower risk of resistance to isoniazid and rifampin (odds ratio [OR] = 0.86, = 0.006 and OR = 0.64, = 0.003 for each 20-year interval, respectively). These data suggest drug resistance in LTBI will remain a challenge and that rifampin-based regimens for treatment of LTBI in non–human immunodeficiency virus–infected adults may be preferable for individuals born in regions with high levels of isoniazid resistance. However, further research is needed to demonstrate whether LTBI treatment based on region of birth further decreases TB reactivation.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.16-0662
2017-03-08
2018-04-21
Loading full text...

Full text loading...

/deliver/fulltext/14761645/96/3/543.html?itemId=/content/journals/10.4269/ajtmh.16-0662&mimeType=html&fmt=ahah

References

  1. Zignol M, Dean AS, Falzon D, van Gemert W, Wright A, van Deun A, Portaels F, Laszlo A, Espinal MA, Pablos-Méndez A, Bloom A, Aziz MA, Weyer K, Jaramillo E, Nunn P, Floyd K, Raviglione MC, , 2016. Twenty years of global surveillance of antituberculosis-drug resistance. N Engl J Med 375: 10811089.[Crossref]
  2. World Health Organization, 2014. Multidrug-Resistant Tuberculosis. 2014 Update. Available at: http://www.who.int/tb/challenges/mdr/mdr_tb_factsheet.pdf?ua=1. Accessed April 30, 2016.
  3. Centers for Disease Control and Prevention, 2014. Trends in Tuberculosis, 2015. Available at: http://www.cdc.gov/tb/publications/factsheets/statistics/tbtrends.htm. Accessed April 30, 2016.
  4. Cain KP, Benoit SR, Winston CA, Mac Kenzie WR, , 2008. Tuberculosis among foreign-born persons in the United States. JAMA 300: 405412.[Crossref]
  5. Posey DL, Naughton MP, Willacy EA, Russell M, Olson CK, Godwin CM, McSpadden PS, White ZA, Comans TW, Ortega LS, Guterbock M, Weinberg MS, Cetron MS, , 2014. Implementation of new TB screening requirements for U.S.-bound immigrants and refugees: 2007–2014. MMWR 63: 234236.
  6. Liu Y, Posey DL, Cetron MS, Painter JA, , 2015. Effect of a culture-based screening algorithm on tuberculosis incidence in immigrants and refugees bound for the United States: a population-based cross-sectional study. Ann Intern Med 162: 420428.[Crossref]
  7. Baker BJ, Winston CA, Liu Y, France AM, Cain KP, , 2016. Abrupt decline in tuberculosis among foreign-born persons in the United States. PLoS One 11: e0147353.[Crossref]
  8. Lobato MN, Mohamed MH, Hadler JL, , 2008. Tuberculosis in a low-incidence US area: local consequences of global disruptions. Int J Tuberc Lung Dis 12: 506512.
  9. Alami NN, Yuen CM, Miramontes R, Pratt R, Price SF, Navin TR, Centers for Disease Control and Prevention (CDC); , 2014. Trends in tuberculosis—United States, 2013. MMWR 63: 229233.
  10. Taylor AB, Kurbatova EV, Cegielski JP, , 2012. Prevalence of anti-tuberculosis drug resistance in foreign-born tuberculosis cases in the U.S. and in their countries of origin. PLoS One 7: e49355.[Crossref]
  11. World Health Organization, 2015. Global Tuberculosis Report 2015. Available at: http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1. Accessed April 30, 2016.
  12. Pareek M, Greenaway C, Noori T, Munoz J, Zenner D, , 2016. The impact of migration on tuberculosis epidemiology and control in high-income countries: a review. BMC Med 14: 48.[Crossref]
  13. Washington State Department of Health, 2014. A Glance at Tuberculosis in Washington State—2014. Available at: http://www.doh.wa.gov/Portals/1/Documents/Pubs/343-108-WTBDFactSheet2014.pdf. Accessed November 14, 2015.
  14. United States Census Bureau, 2015. Quick Facts Washington: People. Available at: https://www.census.gov/quickfacts/table/PST045215/53. Accessed November 14, 2015.
  15. Centers for Disease Control and Prevention, 2014. Reported Tuberculosis in the United States, 2014. Available at: http://www.cdc.gov/tb/statistics/reports/2014/pdfs/tb-surveillance-2014-report_updated.pdf. Accessed November 14, 2015.
  16. Gagneux S, Small PM, , 2007. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis 7: 328337.[Crossref]
  17. World Health Organization, 2016. Diagnosis and Notification of Multidrug-Resistant Tuberculosis. Available at: http://www.who.int/tb/country/data/visualizations/en/. Accessed July 7, 2016.
  18. Nnadi CD, Anderson LF, Armstrong LR, Stagg HR, Pedrazzoli D, Pratt R, Heilig CM, Abubakar I, Moonan PK, , 2016. Mind the gap: TB trends in the USA and the UK, 2000–2011. Thorax 71: 356363.[Crossref]
  19. Rodwell TC, Kapasi AJ, Moore M, Milian-Suazo F, Harris B, Guerrero LP, Moser K, Strathdee SA, Garfein RS, , 2010. Tracing the origins of Mycobacterium bovis tuberculosis in humans in the USA to cattle in Mexico using spoligotyping. Int J Infect Dis 14 (Suppl 3): e129e135.[Crossref]
  20. Centers for Disease Control and Prevention, 2013. Latent Tuberculosis Infection: A Guide for Primary Health Care Providers. Available at: https://www.cdc.gov/tb/publications/ltbi/pdf/targetedltbi.pdf. Accessed July 7, 2016.
  21. Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, Den Boon S, Borroto Gutierrez SM, Bruchfeld J, Burhan E, Cavalcante S, Cedillos R, Chaisson R, Chee CB, Chesire L, Corbett E, Dara M, Denholm J, de Vries G, Falzon D, Ford N, Gale-Rowe M, Gilpin C, Girardi E, Go UY, Govindasamy D, D Grant A, Grzemska M, Harris R, Horsburgh CR, Jr Ismayilov A, Jaramillo E, Kik S, Kranzer K, Lienhardt C, LoBue P, Lönnroth K, Marks G, Menzies D, Migliori GB, Mosca D, Mukadi YD, Mwinga A, Nelson L, Nishikiori N, Oordt-Speets A, Rangaka MX, Reis A, Rotz L, Sandgren A, Sañé Schepisi M, Schünemann HJ, Sharma SK, Sotgiu G, Stagg HR, Sterling TR, Tayeb T, Uplekar M, van der Werf MJ, Vandevelde W, van Kessel F, van't Hoog A, Varma JK, Vezhnina N, Voniatis C, Vonk Noordegraaf-Schouten M, Weil D, Weyer K, Wilkinson RJ, Yoshiyama T, Zellweger JP, Raviglione M, , 2015. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 46: 15631576.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.16-0662
Loading
/content/journals/10.4269/ajtmh.16-0662
Loading

Data & Media loading...

  • Received : 13 Aug 2016
  • Accepted : 19 Nov 2016

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error